Description
Cibor (Bemiparin Sodium) 3500 Solution for Injections 17500ME/ml Syringe 0.2 ml №10
Ingredients:
Each 0.2 ml syringe contains 3500 IU of bemiparin sodium.
Mechanism of Action:
Bemiparin sodium, a low molecular weight heparin, acts as an anticoagulant by potentiating the inhibition of factor Xa, thereby preventing the formation of blood clots.
Pharmacological Properties:
Bemiparin sodium exhibits anticoagulant properties by enhancing the inhibition of factor Xa, leading to the prevention of thrombus formation.
Indications for Use:
Cibor is indicated for the prophylaxis of venous thromboembolism in patients undergoing surgical procedures.
Contraindications:
Cibor should not be administered to patients with active major bleeding or a known hypersensitivity to bemiparin sodium.
Side Effects:
Common side effects of Cibor may include bruising at the injection site, itching, or redness. In rare cases, allergic reactions or bleeding complications may occur.
Usage Instructions:
The recommended dosage of Cibor is one subcutaneous injection of 0.2 ml (3500 IU) daily, preferably in the lower abdomen.
Benefits Compared to Analogues:
In comparative studies, Cibor has demonstrated similar efficacy to other anticoagulants in preventing thromboembolism post-surgery, with a potentially lower risk of side effects, making it a favorable choice in certain patient populations.
Suitable Patient Groups:
Cibor is suitable for adult patients undergoing surgical procedures who require thromboprophylaxis. It is also safe for use in elderly patients and individuals with renal impairment.
Storage Conditions and Shelf Life:
Store Cibor at room temperature away from light and moisture. Check the expiration date on the packaging and do not use the product beyond this date.
Packaging Description:
Cibor is available in packs containing 10 pre-filled syringes, each syringe delivering a fixed dose of 0.2 ml (3500 IU) of bemiparin sodium solution for subcutaneous injection.
Clinical Evidence and Proven Effectiveness:
Clinical studies have demonstrated the efficacy and safety of Cibor in preventing venous thromboembolism in surgical patients. The use of bemiparin sodium has shown a reduction in thrombotic events post-surgery, with a well-tolerated safety profile.
